Cencora reorganizes reporting into three segments for fiscal 2027
Cencora will report three segments from fiscal 2027 after restructuring its operating model, a regulatory filing showed. Revised results for fiscal 2025 and 2026 accompany the change.
Key takeaways
- Cencora (COR) will report three segments starting in fiscal 2027 after restructuring its operating model, a regulatory filing showed on Nov. 4. The company also provided revised segment revenue and operating income for fiscal 2025 and 2026. Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other will be the new segments.
Cencora (COR) will report its results in three segments starting in the first quarter of fiscal 2027, the company said in a regulatory filing on Nov. 4. The change follows a restructuring of its operating model that the company said is intended to strengthen execution and improve visibility. Shares were little changed in regular trading as of 10:26 a.m. ET, from a regular-session close of $340.50.
The Pharmaceutical Distribution and Services segment will cover U.S. and international wholesale pharmaceutical distribution and related services for health systems, retail pharmacies and alternate sites of care.
The Specialty Pharmaceutical and Provider Services segment will include specialty distribution to physician practices and management services organizations, World Courier and third-party logistics services, Innomar and strategic components of PharmaLex.
Other is not a reportable segment. It will continue to hold businesses for which the company is exploring strategic alternatives, including MWI Animal Health, Profarma and the other components of PharmaLex.
To help investors compare, the company provided revised segment revenue and operating income for fiscal 2025 and 2026 under the new structure.
For fiscal 2026, Pharmaceutical Distribution and Services revenue was $284.48 billion, against $271.85 billion in fiscal 2025 as revised. Its operating income was $2.74 billion, up from $2.50 billion.